Amylyx Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Amylyx Pharmaceuticals, Inc. (AMLX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $325.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.43M.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$2.66M, a 175.99% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $3.64M.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$5.96M.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$2.00M, a 161.93% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $3.23M, a 38.21% decline from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $5.22M, a 16.38% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $325.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.11M 10-Q · filed 2026-08-06 | -$3.77M derived: sum of 3 quarters · filed 2026-08-06 | -$127.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$1.43M 10-Q · filed 2026-05-07 | -$4.09M derived: sum of 2 quarters · filed 2026-05-07 | -$452.00K derived: sum of 3 quarters · filed 2026-05-07 | -$6.51M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $981.00K derived: sum of 2 quarters · filed 2026-03-03 | -$5.08M derived: sum of 3 quarters · filed 2026-08-06 | -$5.96M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.42M derived: sum of 2 quarters · filed 2026-08-06 | -$3.30M 10-Q · filed 2025-11-06 | $196.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$6.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$6.94M 10-Q · filed 2026-08-06 | -$6.52M 10-Q · filed 2025-08-07 | -$3.44M derived: sum of 3 quarters · filed 2026-08-06 | -$7.28M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$879.00K 10-Q · filed 2026-05-07 | -$666.00K 10-Q · filed 2025-05-08 | $2.62M derived: sum of 2 quarters · filed 2026-05-07 | -$1.22M derived: sum of 3 quarters · filed 2026-05-07 | -$4.98M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$341.00K derived: sum of 2 quarters · filed 2026-03-03 | -$4.10M derived: sum of 3 quarters · filed 2026-03-03 | -$2.00M 10-K · filed 2026-03-03 | -$4.99M 10-K · filed 2025-03-04 | ||
| 2024-09-30 | -$3.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$7.60M derived: sum of 2 quarters · filed 2025-11-06 | -$5.50M 10-Q · filed 2025-11-06 | -$9.87M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | -$3.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.66M 10-Q · filed 2025-08-07 | -$6.03M derived: sum of 3 quarters · filed 2025-08-07 | $251.00K derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $2.10M 10-Q · filed 2025-05-08 | -$2.27M derived: sum of 2 quarters · filed 2025-05-08 | $4.01M derived: sum of 3 quarters · filed 2025-05-08 | $2.45M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | -$4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.91M derived: sum of 2 quarters · filed 2025-03-04 | $344.00K derived: sum of 3 quarters · filed 2025-03-04 | $3.23M 10-K · filed 2025-03-04 | $4.82M 10-K · filed 2024-02-22 | ||
| 2023-09-30 | $6.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.71M derived: sum of 2 quarters · filed 2024-11-07 | $7.60M 10-Q · filed 2024-11-07 | $9.94M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.32M 10-Q · filed 2024-08-08 | $3.66M derived: sum of 3 quarters · filed 2024-08-08 | $2.49M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $2.88M 10-Q · filed 2024-05-09 | $5.22M derived: sum of 2 quarters · filed 2024-05-09 | $4.05M derived: sum of 3 quarters · filed 2024-05-09 | $3.21M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.17M derived: sum of 2 quarters · filed 2024-02-22 | $331.00K derived: sum of 3 quarters · filed 2024-02-22 | $5.22M 10-K · filed 2024-02-22 | |||
| 2022-09-30 | -$1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.01M derived: sum of 2 quarters · filed 2023-11-09 | $2.88M 10-Q · filed 2023-11-09 | $5.60M derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2022-06-30 | -$837.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.05M 10-Q · filed 2023-08-10 | $6.78M derived: sum of 3 quarters · filed 2024-02-22 | $7.87M derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2022-03-31 | $4.89M 10-Q · filed 2023-05-11 | $7.61M derived: sum of 2 quarters · filed 2024-02-22 | $8.71M derived: sum of 3 quarters · filed 2024-02-22 | $9.13M derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2021-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $3.82M derived: sum of 2 quarters · filed 2024-02-22 | $4.24M derived: sum of 3 quarters · filed 2024-02-22 | $4.49M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.52M derived: sum of 2 quarters · filed 2022-11-10 | $1.76M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $421.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $665.00K 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | $244.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |